An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Peng, Songlin ^a   Zhao, Yang ^a   Xu, Feng ^a   Jia, Changjun ^a   Xu, Yongqing ^a   Dai, Chaoliu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; CAPECITABINE; DOXORUBICIN; PLACEBO; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER CELL CARCINOMA; META ANALYSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; TUMOR INVASION; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; LIVER NEOPLASMS; PATIENT SAFETY; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PATIENT SAFETY; PHENYLUREA COMPOUNDS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84914669556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112530     Document Type: Article

References (42)

1. Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42 Suppl 3: S206-S214.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711.
3. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
4. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
6. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844.
7. Adnane L, Trail PA, Taylor I, Wilhelm SM (2006) Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612.
8. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334.
9. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57: 821-829.
10. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 48: 1452-1465.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
12. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135: 982-989.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
14. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
16. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
17. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
19. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, et al. (2011) Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 34: 949-959.
20. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, et al. (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54: 2055-2063.
21. Yang Y, Lu Y, Wang C, Bai W, Qu J, et al. (2012) Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys 63: 159-169.
22. Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, et al. (2013) Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol 30: 345.
23. Trojniak MP, Palozzo AC, Mazurek M, Jirillo A (2012) Sorafenib in hepatocellular carcinoma - a post marketing evaluation. Immunopharmacol Immunotoxicol 34: 419-422.
24. Song T, Zhang W, Wu Q, Kong D, Ma W (2011) A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol 23: 1233-1238.
25. Balsom SM, Li X, Trolli E, Rose J, Bloomston M, et al. (2010) A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology 78: 210-212.
26. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, et al. (2009) Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115: 428-436.
27. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300.
28. Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, et al. (2010) Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 66: 837-844.
29. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, et al. (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47: 2117-2127.
30. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, et al. (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31: 4067-4075.
31. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, et al. (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304: 2154-2160.
32. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
33. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, et al. (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31: 3517-3524.
34. Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, et al. (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 30: 655.
35. Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, et al. (2012) Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 11: 458-466.
36. Wang Z, Wu XL, Zeng WZ, Xu GS, Xu H, et al. (2013) Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev 14: 691-694.
37. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35-S50.
38. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, et al. (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29: 62-67.
39. (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751-755.
40. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
41. Wood LS (2006) Managing the side effects of sorafenib and sunitinib. Community Oncol 3: 558-562.
42. Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864-880.